FOLH1 and neoplasm: Moreover, the tumor-to-kidney dose ratio of [177Lu]Lu-Ibu-PSMA-02 was significantly higher than for [177Lu]Lu-Ibu-PSMA-01, which is a favorable characteristic in view of a therapeutic application.